PACILLI, ANNALISA
 Distribuzione geografica
Continente #
NA - Nord America 1.913
EU - Europa 1.231
AS - Asia 278
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.428
Nazione #
US - Stati Uniti d'America 1.910
RU - Federazione Russa 465
IT - Italia 208
PL - Polonia 176
IE - Irlanda 121
CN - Cina 102
SE - Svezia 96
SG - Singapore 77
HK - Hong Kong 48
CH - Svizzera 43
DE - Germania 43
JO - Giordania 26
FR - Francia 24
FI - Finlandia 21
IN - India 16
GB - Regno Unito 14
ES - Italia 11
CI - Costa d'Avorio 5
VN - Vietnam 4
CA - Canada 3
UA - Ucraina 3
BE - Belgio 2
KR - Corea 2
NL - Olanda 2
RO - Romania 2
EU - Europa 1
MY - Malesia 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 3.428
Città #
Santa Clara 302
Fairfield 260
Warsaw 176
Ashburn 149
Woodbridge 135
Chandler 134
Seattle 131
Dublin 121
Cambridge 106
Wilmington 96
Houston 88
Singapore 54
Altamura 53
Ann Arbor 49
Lawrence 48
Florence 47
Bern 43
Princeton 41
Beijing 38
Hong Kong 28
Buffalo 25
Bremen 24
Boston 21
Moscow 21
San Diego 17
Mumbai 16
Los Angeles 15
Shanghai 15
New York 13
Barcelona 11
Medford 10
Kent 9
Boardman 8
Rome 8
Dearborn 7
Helsinki 6
Hillsboro 6
Pian di Scò 6
Abidjan 5
Norwalk 5
Dong Ket 4
Falls Church 4
Jacksonville 4
London 4
Milan 4
Paris 4
Redwood City 4
Romainville 4
Faenza 3
Fiesole 3
Fuzhou 3
Munich 3
Pavia 3
Rochester 3
Andover 2
Brussels 2
Burghausen 2
Cagliari 2
Cantagallo 2
Costa Mesa 2
Gambettola 2
Hefei 2
Nanjing 2
Nürnberg 2
Padova 2
Phoenix 2
Prato 2
Red Deer 2
San Gavino Monreale 2
Seoul 2
Siena 2
Villa Minozzo 2
Wandsworth 2
Wuhan 2
Yubileyny 2
Acton 1
Atlanta 1
Azzano Decimo 1
Azzano San Paolo 1
Baotou 1
Bari 1
Brescia 1
Böblingen 1
Capena 1
Chiswick 1
Clifton 1
Duncan 1
Falkenstein 1
Fontebuona 1
Fremont 1
Guangzhou 1
Harbin 1
Iasi 1
Imperia 1
Islington 1
Jinan 1
Kaohsiung 1
Kilburn 1
Leawood 1
Lugo di Vicenza 1
Totale 2.464
Nome #
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 264
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 179
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 172
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 154
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 149
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 149
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 145
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 142
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 139
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 135
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 133
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 125
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 124
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 118
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 117
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 109
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 105
Novel insights into myelofibrosis pathophysiology and treatment 102
Validation of the Mayo alliance prognostic system for mastocytosis 99
Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling, human myelofibrosis 98
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 98
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice? 94
Prognotic Impact of Mutations in Systemic Mastocytosis 85
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. 81
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 78
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 78
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 67
Genetic lesions disrupting calreticulin 3′-untranslated region in JAK2 mutation-negative polycythemia vera 59
Prognostic relevance of mutations in myelofi-brosis 58
null 47
Totale 3.503
Categoria #
all - tutte 9.897
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.897


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020564 0 0 0 0 87 86 92 98 75 46 63 17
2020/2021345 26 34 13 80 12 13 16 25 35 45 28 18
2021/2022211 5 5 24 9 14 13 9 22 13 7 35 55
2022/2023725 59 153 49 51 37 100 81 47 77 6 18 47
2023/2024244 10 21 29 12 30 28 3 61 4 17 16 13
2024/2025959 56 151 117 260 375 0 0 0 0 0 0 0
Totale 3.503